Pfizer (PFE) BioNTech (BNTX) will stop US COVID-19 vaccine study in healthy adults ages 50 to 64 due to slow enrollment
Context
The decision for Pfizer and BioNTech to halt their COVID-19 vaccine study in the specified age group reflects challenges in enrollment, which may signal concerns over vaccine uptake or market saturation. This development could impact investor sentiment regarding their vaccine-related revenue projections, and may also affect broader market confidence in vaccine advancements and public health strategies.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#PFIZER INC#PFE.US#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#PFE#US EQUITIES